In a large meta-analysis involving over 31,000 participants with and without T2DM, SGLT2 inhibitors significantly reduced serum UA levels by an average of 31.5 μmol/L in diabetic individuals and by as much as 91.4 μmol/L in non-diabetic subjects [121]. Here, SLC5A2 is linked to type 2 diabetes mellitus.